NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Medical Instruments & Supplies · USD

Pulse Biosciences, Inc. (PLSE) Stock Analysis

Pulse Biosciences, Inc. (PLSE) is a Medical Instruments & Supplies stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

PLSE

$51.31

+$0.47 (+0.92%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PLSE with… →

PLSE Key Statistics

As of Oct 21, 2026
Trading
Open
$51.16
Previous Close
$50.84
Day's Range
50.07–52.02
52-Week Range
12.56–58.90
Volume
315.59K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.57
Valuation
Market Cap
$3.66B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3,088.24
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.18
Financials (FY)
Revenue (FY)
$350.00K
Net Income (FY)
−$72.78M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
71.32M
1-Year Return
+183.79%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
522.23K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, PLSE closed at $51.31, +183.79% over 1 year.

Pulse Biosciences, Inc. (PLSE) has a market capitalization of $3.66B.

In fiscal 2025, PLSE reported revenue of $350.00K.

PLSE Stock Return by Calendar Year

Pulse Biosciences, Inc. (PLSE) 10-year return: what $10,000 became

1 year
$10,000 $28,379
+183.79%
5 years
$10,000 $22,957
+129.57%
10 years
$10,000 $88,313
+783.13%

If you had invested $10,000 in Pulse Biosciences, Inc. (PLSE) 10 years ago, at the close on October 21, 2016, it would have been worth $88,313 at the close on October 21, 2026: +783.13% in total, +24.34% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+273.71%
2025−21.14%
2024+42.24%
2023+341.88%
2022−81.30%
2021−37.93%
2020+77.93%
2019+17.02%
2018−51.44%
2017+263.08%
2016 (partial year)+42.86%

As of October 21, 2026.

PLSE Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$350.00K−$72.78M−20,794.6%
2024$0.00−$53.59M—
2023$0.00−$42.21M—
2022$700.00K−$58.51M−8,357.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$350.00K−$189.00K−$76.94M−$72.78M−20,794.6%
2024$0.00$0.00−$56.26M−$53.59M—
2023$0.00$0.00−$43.57M−$42.21M—
2022$700.00K−$11.24M−$58.06M−$58.51M−8,357.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Pulse Biosciences, Inc. (PLSE) carries a market capitalisation of $3.66B. It is classified in the Medical Instruments & Supplies industry, within the Healthcare sector. Headcount on file is 116.

PLSE last closed at $51.31 on October 21, 2026. That is +$0.47 (+0.92%) against the previous close. Over the past 52 weeks the price has ranged from $12.56 to $58.90. The latest close sits 308.52% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $350.00K. The same year closed with a net loss of $72.78M. Earnings per share on a trailing basis come to −1.18.

Across the 4 fiscal years on file, revenue moves from $700.00K in 2022 to $350.00K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 3,088.24. On price-to-sales that is 1,188.8 times the Medical Instruments & Supplies median of 2.6. 50 Medical Instruments & Supplies companies report these metrics, and the medians quoted come from that group.

The trailing one-year total return is +183.79%. Measured over 10 years, that is +24.34% a year compounded. The reported beta is 1.57. Annualized volatility over the trailing 10 years is 92.31%.

Growth & Income

The record shows no dividend for PLSE.

The strongest complete calendar year on file is 2023 at +341.88%; the weakest is 2022 at −81.30%. Of the 9 complete calendar years on file, 5 finished higher. So far in 2026 the total return is +273.71%.

Peer Comparison

Pulse Biosciences, Inc. (PLSE) operates in the Medical Instruments & Supplies industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Pulse Biosciences, Inc. PLSE $3.66B —
Intuitive Surgical, Inc. ISRG $151.25B 51.8
Becton, Dickinson and Company BDX $52.79B 45.1
Medline Inc. MDLN $47.51B 88.3

The Medical Instruments & Supplies industry average P/E ratio is 31.2x. Pulse Biosciences, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Medical Instruments & Supplies Stocks

ISRG

Intuitive Surgical, Inc.

$151.25B

 BDX

Becton, Dickinson and Company

$52.79B

 MDLN

Medline Inc.

$47.51B

 RMD

ResMed Inc.

$34.63B

 ALC

Alcon Inc.

$32.60B

 WST

West Pharmaceutical Services, Inc.

$27.69B
View all Medical Instruments & Supplies stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Pulse Biosciences, Inc.

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

Visit website →